论文部分内容阅读
目的探讨阿卡波糖片联合二甲双胍治疗2型糖尿病的临床疗效。方法选取2011年3月—2014年6月石嘴山监狱医院收治的2型糖尿病患者168例,随机分为试验组与对照组,各84例。对照组患者予以二甲双胍治疗,试验组患者在对照组基础上加用阿卡波糖片治疗。观察两组患者治疗前后空腹血糖(FBG)、餐后血糖(PBG)水平、临床疗效及不良反应发生情况。结果治疗前两组患者FBG水平比较,差异无统计学意义(P>0.05);治疗后试验组患者FBG水平低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者PBG比较,差异无统计学意义(P>0.05);治疗后试验组患者PBG水平低于对照组,差异有统计学意义(P<0.05)。试验组患者总有效率高于对照组,差异有统计学意义(P<0.05);试验组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论阿卡波糖片联合二甲双胍治疗2型糖尿病的临床疗效显著,可有效控制患者血糖,且不良反应少。
Objective To investigate the clinical efficacy of acarbose plus metformin in the treatment of type 2 diabetes mellitus. Methods A total of 168 type 2 diabetic patients treated in Shizuishan Prison Hospital from March 2011 to June 2014 were randomly divided into experimental group and control group, with 84 cases in each group. Patients in the control group were treated with metformin. Patients in the test group were treated with acarbose on the basis of the control group. The fasting blood glucose (FBG), postprandial blood glucose (PBG) levels, clinical efficacy and adverse reactions of the two groups before and after treatment were observed. Results There was no significant difference in FBG levels between the two groups before treatment (P> 0.05). After treatment, the level of FBG in the experimental group was lower than that in the control group (P <0.05). There was no significant difference in PBG between the two groups before treatment (P> 0.05). The level of PBG in the experimental group was lower than that in the control group after treatment (P <0.05). The total effective rate of the experimental group was higher than that of the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group was lower than that of the control group, the difference was statistically significant (P <0.05). Conclusion Acarbose combined with metformin in the treatment of type 2 diabetes has obvious curative effect, which can effectively control the blood sugar of patients with less adverse reactions.